Related Experiment Video

Updated: Jun 22, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

What can ongoing clinical trials of anticoagulants demonstrate?

Jonathan L Halperin1

  • 1Mount Sinai Medical Center, New York, New York 10029-6574, USA. jonathan. halperin@mssm.edu

Journal of Cardiovascular Medicine (Hagerstown, Md.)
|June 26, 2009
PubMed

Insights

New anticoagulants are crucial for managing increasing thromboembolic disease in aging populations. Clinical trials are essential for evaluating these novel drugs, aiming for optimal prophylactic anticoagulation therapy.

Area of Science:

  • Cardiology and Pharmacology
  • Geriatric Medicine
  • Hematology

Background:

  • Aging populations face a growing burden of thromboembolic diseases.
  • Vitamin K antagonists have limitations, necessitating the development of novel anticoagulants.
  • Effective anticoagulation is vital for managing conditions like atrial fibrillation and post-operative venous thromboembolism.

Purpose of the Study:

  • To review the clinical evaluation of new anticoagulant therapies.
  • To highlight the importance of evidence-based data from clinical trials for novel anticoagulants.
  • To discuss the development of anticoagulants targeting thrombin and Factor X.

Main Methods:

  • Review of clinical trial methodologies, including blinding, control groups, and patient selection.
  • Examination of data from trials investigating oral direct thrombin inhibitors (e.g., ximelagatran).
  • Discussion of emerging anticoagulant strategies focusing on Factor X inhibition.

Main Results:

  • Clinical trials demonstrate the efficacy of novel anticoagulants, such as oral direct thrombin inhibitors, for thromboembolism prevention.
  • Methodological considerations in clinical trials significantly impact the interpretation of results.
  • Targeting Factor X represents a promising avenue for new anticoagulant development.

Conclusions:

  • Novel anticoagulants offer an advance over traditional therapies, addressing limitations of vitamin K antagonists.
  • Rigorous clinical trial evaluation is paramount for establishing the safety and efficacy of new anticoagulants.
  • Continued research and evidence-based data will lead to optimized prophylactic anticoagulation strategies.

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...